ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1095

IFN Gene Expression Correlates with Frequency of Circulating Switched Memory B-Cells in Patients with Incomplete Systemic Lupus Erythematosus

Wietske Lambers1, Geert Lanting1, Wayel H. Abdulahad2, Hendrika Bootsma2, Johanna Westra2 and Karina de Leeuw3, 1Rheumatology/Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, 2Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands, 3Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: B cells, Biomarkers, interferons and pathogenesis, SLE

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Systemic Lupus Erythematosus – Etiology and Pathogenesis Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

Incomplete systemic lupus erythematosus (iSLE) includes patients with typical features of SLE, who do not meet classification criteria. Still, up to 50% will develop SLE in the future. Follow-up of these iSLE patients can potentially unravel the pathogenesis of SLE.  Interferon (IFN) type-I is an important early mediator in SLE. Furthermore, B cells are considered to be the main culprits in SLE pathogenesis, owing to their production of autoantibodies. The purpose of this research is assessing whether IFN gene upregulation is associated with alteration in B-cell subset distribution in iSLE patients.

Methods:

Thirty-four iSLE patients (ANA titer ≥1:80, ≥1 ACR clinical feature), 38 SLE patients with quiescent disease (SLEDAI ≤ 4) and 11 HC were included. B-cell subsets were determined in peripheral blood mononuclear cells (PBMC) by flow cytometry based on surface markers and were subdivided into naïve B-cells (CD27–CD38-/low), transitional B-cells (CD27–CD38High), plasma cells (CD27HighCD38High), and memory cells (CD27+), of which the latter were subdivided into switched (IgD–IgM–) and non-switched (IgD+IgM+) memory B cells.

Simultaneously, RNA was isolated from whole blood using PAXgene tubes and reversely transcribed to cDNA and quantitatively analyzed by RT-PCR. IFN score was calculated based on cumulative expression of 3 IFN-related transcripts (IFI44L, LY6E, MX1).

Results:

Baseline characteristics are shown in Table 1. SLE patients had decreased non-switched memory cells and increased switched memory cells in comparison with iSLE patients and HC (figure 1). Other subsets were statistically comparable between the groups. The IFN score was increased in 17/32 iSLE patients (53%) and 24/38 SLE patients (63%). Remarkably, in iSLE patients, IFN score correlated positively with percentages of switched memory cells (figure 2, r=0. 45, p=0.009), plasma cells (r=0.42, p=0.01), transitional B-cells (r=0.47, p=0.006) and negatively with non-switched memory cells (r=-0.47, p=0.007). In SLE, IFN score correlated with transitional B-cells (r=0.47, p=0.003), naïve B-cells (r=0.47, p=0.003) and negatively with total memory B-cells (r=-0.41, p=0.01), but not with switched or non-switched memory cells. 

Conclusion:

Although lower proportions of circulating switched memory B cells were seen in iSLE compared to SLE patients, IFN score in iSLE patients correlates strongly with switched memory cells. This could imply that IFN expression triggers progression to SLE by stimulating isotype switching of B-cells.

 

HC

(n=11)

iSLE

(n=34)

SLE

(n=38)

Female gender , n ( %)

9 (82)

27 (79)

32 (84)

Age, median (range)

34 (26-64)

46 (18-84)

42 (19-74)

Disease duration, years,

median (range)           

1.2 (0.1-4.6)

3.1 (0.5-6.8)

ACR criteria, median (range)

3 (1-3)

5 (2-9)

SLICC criteria, median (range)

3 (1-4*)

5 (4-9)

SLEDAI median (range)

0 (0-6)

2 (0-4)

Hydroxychloroquine use, n (%)

10 (30)

31 (82)

Immunologic features, n (%)

  ANA or SSA-pattern pos (%)

34 (100)

39 (100)

  Anti-dsDNA pos (%)

9 (26)

32 (84)

  Anti-SSA pos (%)

15 (44)

13 (34)

  Anti-Sm pos (%)

2 (6)

7 (18)

  Decreased complement pos (%)

5 (19)

23 (62)


Disclosure: W. Lambers, None; G. Lanting, None; W. H. Abdulahad, None; H. Bootsma, None; J. Westra, None; K. de Leeuw, None.

To cite this abstract in AMA style:

Lambers W, Lanting G, Abdulahad WH, Bootsma H, Westra J, de Leeuw K. IFN Gene Expression Correlates with Frequency of Circulating Switched Memory B-Cells in Patients with Incomplete Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/ifn-gene-expression-correlates-with-frequency-of-circulating-switched-memory-b-cells-in-patients-with-incomplete-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/ifn-gene-expression-correlates-with-frequency-of-circulating-switched-memory-b-cells-in-patients-with-incomplete-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology